Drugs / VBI-2901e
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05614245 | Mar 2023 → Jun 2024 | COVID-19 | VBI Vaccines Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBI-2901e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05614245 ↗ |
| Modality | Vaccine | “VBI-2901e is an investigational trivalent COVID-19 vaccine candidate” NCT05614245 ↗ |
| Route | Intramuscular | “Intramuscular injection of VBI-2901e” NCT05614245 ↗ |